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Case Report
Maculopathy Associated with Tacrolimus (FK 506)
Taehyuk Koh, Seung-Hee Baek, Jung Il Han, Ungsoo Samuel Kim
Myung-Gok Eye Research Institute, Department of Ophthalmology, Kim’s Eye Hospital, 
Konyang University College of Medicine, Seoul, Korea
A 63-year-old man with a history of liver transplantation presented to our clinic complaining of visual disturbance. He 
had been receiving tacrolimus (FK 506) for 30 months (6 mg/day for 2 years and 3 mg/day for 6 months); he re-
ported that the visual disturbance began while taking tacrolimus. A full ophthalmologic examination and electro-
physiologic and imaging studies were performed. The best corrected visual acuity was 0.1 in both eyes. There were 
no abnormal finding in the anterior segment, pupillary reflexes were normal and, there was no swelling in either optic 
disc. Although the foveal reflex was slightly decreased, fluorescein angiography revealed non-specific signs, with 
the exception of a window defect. A multifocal electro-retinogram revealed decreased amplitude of the central ring. 
A Swedish interactive threshold algorithm-standard 10-2 visual field test revealed a central scotoma. These findings 
suggest that tacrolimus may result in maculopathy. Therefore, careful ophthalmologic examination is necessary in 
the patients taking tacrolimus.
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Tacrolimus (FK 506; Prograf, Fujisawa USA Inc., Deerfield, 
IL, USA), a fungal metabolite produced by Streptomyces 
tsukubaenis, is an effective immunosuppressive agent used 
in bone marrow and organ transplantation patients. Tacrolimus 
inhibits cytokine synthesis and blocks T-cell development. 
Cortical blindness associated with bilateral occipital white 
matter lesions and bilateral optic neuropathy was reported in 
one patient on tacrolimus [1-3]. However, there have been no 
reports of maculopathy associated with the use of this agent. 
We report a patient who developed maculopathy in both eyes 
as a possible complication of tacrolimus therapy.
Case Report
In August 2008, a 63-year-old man presented with gradual 
onset blurry vision in both eyes. He had initially developed 
the visual disturbance one year prior at that time, his best 
corrected visual acuity was 20/30 in both eyes. On slit lamp 
examination, the anterior and posterior segments of both 
eyes showed no significant findings and further ophthalmologic 
exam was not performed. He had a history of liver transplantation 
for chronic hepatitis B-related cirrhosis, 2 years prior to presentation. 
He denied any other significant medical history, including 
hypertension, diabetes mellitus, and trauma. He also had no 
significant family history and no clinical or laboratory signs 
of a graft versus host reaction. He had been taking tacrolimus 
(Prograf) for 30 months (6 mg for 2 years and 3 mg for 6 
months) and had noted the gradual onset of the visual 
disturbance in conjunction with the immunosuppressive 
therapy. He had also been taking multiple other drugs, including 
digestives, antihistamines, expectorants, and Cellcept (Syntex 
Puerto Rico Inc., Humacao, Puerto Rico).
His best corrected visual acuity was 20/200 in both eyes. 
Both pupils were reactive to light, and no relative afferent pu-
pillary defect was noted. The intraocular pressure was 9 
mmHg in the right eye and 10 mmHg in the left eye. Both 
lenses were mildly opacified on slit lamp examination. The 
Ishihara color test showed total dyschromatopsia in both 
eyes. No swelling or pallor was noted in either optic disc. 
Although the foveal reflex was slightly decreased, no bulls 
eye phenomenon was noted. Fluorescein angiography re-
vealed non-specific signs, with only a window defect caused 
by retinal pigment epithelium (RPE) atrophy (Fig. 1). Optical 
coherence tomography also revealed non-specific finding in 
the fovea (Fig. 2). Electroretinography (ERG) demonstrated 
a delayed a wave and b wave latency during the photopic re-Korean J Ophthalmol Vol.25, No.1, 2011
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Fig. 1. Fundus photography and fluorescein angiography revealed non-specific findings in both eyes.
sponse; the response amplitude was slightly decreased in the 
left eye. Multifocal ERG showed decreased amplitude in the 
central ring one in both eyes (Fig. 3A and 3B). The Humphrey 
perimeter (Humphrey Instruments Inc., San Leandro, CA, 
USA) static visual field with central 10-2 threshold test re-
vealed a central scotoma (Fig. 3C and 3D). Visual evoked po-
tential (VEP) testing demonstrated a P100 delay in both eyes 
(Fig. 4). A coagulation factor deficiency was not found and 
the platelet count was within the normal range on serologic 
testing. Computed tomography revealed no abnormalities. 
At the final visit, the patient’s best corrected visual acuity 
was maintained at 20/200 in both eyes, some RPE changes 
were observed on fundus examination.
Discussion
In patients taking tacrolimus, several factors may lead to 
visual disturbance. First, such patients may develop optic 
neuropathy. Brazis et al. [1] reported that bilateral optic 
neuropathy may stem from the direct neurotoxic effects of 
tacrolimus. Although VEP testing demonstrated a mild P100 
delay, the present patient did not exhibit disc swelling or disc 
pallor. A mild, focal, central scotoma was noted on visual field 
testing and foveal suppression was observed on multifocal T Koh, et al. Maculopathy with Tacrolimus
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Fig. 2. Optical coherence tomography of the macular area revealed 
no definite abnormal findings.
C  D
A B
Central 10-2 threshold test Central 10-2 threshold test
Pattern standard deviation Pattern standard deviation
MD: -1.85 db p< 10%
PSD: 1.58 db p < 10%
MD: -0.69 db
PSD: 2.12 db p < 2%
Right eye Left eye
Right eye Left eye
Fig. 3. The multifocal electroretinogram demonstrated foveal sup-
pression in both eyes (A,B). A central scotoma was noted on central 
10-2 threshold visual field testing (C,D). MD = mean deviation; 
PSD = pattern standard deviation.
Fig. 4. Visual evoked potential (VEP) revealed P100 delay in both 
eyes.
ERG. Therefore, maculopathy was considered a more likely 
source of the visual disturbance than optic neuropathy.
Cortical blindness is another possible cause of symptoms 
in patients such as the one described in this report. Magnetic 
resonance imaging easily demonstrates the white matter 
lesions attendant to tacrolimus and cyclosporine toxicity 
[2]. Although magnetic resonance imaging was not performed 
in this patient because of claustrophobia, brain computed 
tomography revealed no abnormalities. Therefore, this patient’s 
visual disturbance was unlikely to have been associated 
with cortical blindness.
We have no definitive explanation for the mechanism 
behind the maculopathy in this patient. Tacrolimus may have 
a direct neurotoxic effect on the RPE, cone cells, or rod cells. 
Furthermore, vasoconstriction may be induced along with 
the maculopathy, resulting in neural tissue damage and tissue 
ischemia [2]. Furthermore, another possible mechanism for 
the development of maculopathy could involve focal proliferation 
and loss of the RPE, predominantly in the fovea, similar to 
that seen with cyclophosphamide and cytarabine in a patient 
with central nervous system lymphoma [4]. In conclusion, 
we suggest that tacrolimus may cause retinal maculopathy. 
Therefore, careful ophthalmologic examination is necessary 
in patients taking tacrolimus.
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